Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VOR Vor Biopharma Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.6500

+0.0000

0.00%

盘后0.6500

+0.00000.00%

18:06 EDT

High0.6994	Low0.6300	Vol121.87K
Open0.6511	D1 Closing0.6500	Amplitude10.68%
Mkt Cap81.15M	Tradable Cap25.35M	Total Shares124.85M
T/O79.69K	T/O Rate0.31%	Tradable Shares38.99M
P/B0.84	ROE-94.52%	EPS-1.70
52wk High1.95	52wk Low0.4900	P/E-0.38
Dividend0.00	Div.Yield0.00	ROA-44.42%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"VOR","market":"US","secType":"STK","nameCN":"Vor Biopharma Inc.","latestPrice":0.65,"timestamp":1744920000000,"preClose":0.65,"halted":0,"volume":121866,"hourTrading":{"tag":"盘后","latestPrice":0.65,"preClose":0.65,"latestTime":"18:06 EDT","volume":849,"amount":553.3125,"timestamp":1744927568628},"delay":0,"floatShares":38992886,"shares":124851547,"eps":-1.701665,"marketStatus":"Closed Good Friday","change":0,"latestTime":"04-17 16:00:00 EDT","open":0.6511,"high":0.6994,"low":0.63,"amount":79685.5085346,"amplitude":0.106769,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.701665,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":0.65,"preHourTrading":{"tag":"盘前","latestPrice":0.6825,"preClose":0.65,"latestTime":"09:15 EDT","volume":1204,"amount":854.7299544,"timestamp":1744895759324},"postHourTrading":{"tag":"盘后","latestPrice":0.65,"preClose":0.65,"latestTime":"18:06 EDT","volume":849,"amount":553.3125,"timestamp":1744927568628},"volumeRatio":0.6932815424430041,"impliedVol":1.2947,"impliedVolPercentile":0.8725},"requestUrl":"/m/hq/s/VOR","defaultTab":"news","newsList":[{"id":"2526826238","title":"We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2526826238","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526826238?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 00:53","pubTimestamp":1744131216,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma/news/were-a-little-worried-about-vor-biopharmas-nasdaqvor-cash-bu-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USAW.SI","BK4139","USJW.SI","BK4588","LU2095319765.USD","BK4112","TSYW.SI","MNQmain","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR",".IXIC","LU2210150020.SGD","VOR","IE00B64PRP62.GBP","NQmain","IE00B3QW5Z07.USD","NVIW.SI","PSQ","NDAQ","QID","QLD","IE00BKPKM429.USD","TQQQ","SQQQ"],"gpt_icon":1},{"id":"2523294796","title":"Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2523294796","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523294796?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:52","pubTimestamp":1743425550,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So, the natural question for Vor Biopharma  shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.Does Vor Biopharma Have A Long Cash Runway?Since it has a market capitalisation of US$94m, Vor Biophar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-vor-biopharma-nasdaq-125230404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","IE00B64PRP62.GBP","SQQQ","BK4585","BK4112","TQQQ","VOR","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","TSYW.SI","MNQmain","NVIW.SI","BK4588","NQmain","QID","LU2210150020.SGD","NDAQ","QLD","USAW.SI",".IXIC","LU2210149790.SGD","IE00B3QW5Z07.USD","PSQ","BK4139"],"gpt_icon":1},{"id":"2523689108","title":"Optimistic Buy Rating for Vor Biopharma Amidst Economic Challenges and Promising Clinical Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2523689108","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523689108?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:55","pubTimestamp":1743184522,"startTime":"0","endTime":"0","summary":"Vor Biopharma (VOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from Jones...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-vor-biopharma-amidst-economic-challenges-and-promising-clinical-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-vor-biopharma-amidst-economic-challenges-and-promising-clinical-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2521001064","title":"Vor Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521001064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521001064?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 19:45","pubTimestamp":1742557500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 07:45 ET (11:45 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2521494134","title":"Vor Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521494134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521494134?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 05:10","pubTimestamp":1742505048,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc reports results for the quarter ended December 31 - Earnings SummaryVor Biopharma Inc VOR.OQ reported a quarterly adjusted loss of 44 cents per share for the quarter ended December 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL8N3Q32EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2521949413","title":"BRIEF-Vor Biopharma Inc Files For Mixed Shelf Offering Of Up To $350 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521949413","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521949413?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 05:09","pubTimestamp":1742504955,"startTime":"0","endTime":"0","summary":"BRIEF-Vor Biopharma Inc Files For Mixed Shelf Offering Of Up To $350 MillionMarch 20 (Reuters) - Vor Biopharma Inc VOR.O:VOR BIOPHARMA INC: FILES FOR MIXED SHELF OFFERING OF UP TO $350 MILLION - SEC FILINGFurther company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q3100:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2521494831","title":"Vor Bio files $350M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2521494831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521494831?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:50","pubTimestamp":1742503835,"startTime":"0","endTime":"0","summary":"16:47 EDT Vor Bio (VOR) files $350M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vor-bio-files-350m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vor-bio-files-350m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2521491999","title":"Vor Biopharma Inc: Files for Mixed Shelf Offering of up to $350 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2521491999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521491999?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:46","pubTimestamp":1742503599,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q3100:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2521496084","title":"Vor Biopharma FY 2024 GAAP EPS $(1.70) Misses $(1.40) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496084","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496084?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:13","pubTimestamp":1742501630,"startTime":"0","endTime":"0","summary":"Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $(1.40) by 21.43 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44425101/vor-biopharma-fy-2024-gaap-eps-1-70-misses-1-40-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vor Biopharma FY 2024 GAAP EPS $(1.70) Misses $(1.40) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2521849960","title":"Vor Biopharma: Projected to Fund Operations Into the First Quarter of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2521849960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521849960?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA4Y2PHM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2521496938","title":"Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496938?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA4Y2PHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2521496186","title":"Press Release: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496186","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496186?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- VCAR33 clinical data update planned for first half of 2025 and trem-cel +. Mylotarg clinical data update planned for second half of 2025. -- Anticipate initiation of the first trem-cel+VCAR33 Treatment System. CAMBRIDGE, Mass., March 20, 2025  -- Vor Bio , a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.\"We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our clinical trials reinforces our confidence in the potential of trem-cel and VCAR33 to transform the treatment landscape,\" said Dr. Robert Ang, Vor Bio's President and Chief Executive Officer. \"With a strengthened financial position from recent investment by new investor Reid Hoffman and existing investor RA Capital Management, we are well-positioned to drive our mission forward and deliver meaningful impact to patients.\".","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPE","BK4139","VOR"],"gpt_icon":0},{"id":"2519771748","title":"Vor Biopharma Inc  expected to post a loss of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519771748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519771748?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:18","pubTimestamp":1741951101,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc  expected to post a loss of29cents a share - Earnings Preview Vor Biopharma Inc VOR.OQ VOR.O is expected to show no change in quarterly revenue when it reports  results on March 18 (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX0UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2511523542","title":"Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2511523542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511523542?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 21:00","pubTimestamp":1739451604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA6DPTY1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2511542459","title":"Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2511542459","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511542459?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 21:00","pubTimestamp":1739451600,"startTime":"0","endTime":"0","summary":"Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy  clinical trials. CAMBRIDGE, Mass., Feb. 13, 2025  -- Vor Bio , a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy  trials. The data, which was presented at the TANDEM Meetings of ASTCT and CIBMTR, demonstrated the need to improve the process and experience of patients considering and enrolling in CGT trials.Educating patients and enrolling them in CGT trials requires more time compared to non-CGT trials due to their complexity and patients’ need for additional reassurance or emotional support.The results reveal significant opportunities for institutions and trial sponsors to improve the patient experience, streamline the process, and enroll more patients in CGT tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vor-bio-presents-novel-research-130000430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2509826817","title":"Vor Biopharma Approves Stock Option Repricing Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2509826817","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509826817?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 05:41","pubTimestamp":1738878098,"startTime":"0","endTime":"0","summary":"Vor Biopharma ( ($VOR) ) has shared an update. On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-approves-stock-option-repricing-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-approves-stock-option-repricing-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4516","BK4139","BK4600","BK4595","BK4588","BK4023","BK4596","BK4585"],"gpt_icon":0},{"id":"2508611003","title":"Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2508611003","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508611003?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 21:00","pubTimestamp":1738587600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb. 03, 2025  -- Vor Bio , a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFireside Chat: Wednesday, February 12th at 12:00pm ET Location: Virtual. A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vor-bio-participate-oppenheimers-35th-130000997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VOR","BK4137","BK4139","BK4127","OPY","HCSG"],"gpt_icon":0},{"id":"2506730215","title":"Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross","url":"https://stock-news.laohu8.com/highlight/detail?id=2506730215","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506730215?lang=en_us&edition=full_marsco","pubTime":"2025-01-27 22:55","pubTimestamp":1737989702,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc.  is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a \"golden cross.\". There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.Once investors consider VOR's positive earnings outlook for the current quarter, the bullish case only solidifies. No earnings estimate has gone lower in the past two months compared to 1 revisions higher, and the Zacks Consensus Estimate has increased as well.Given this move in earnings estimates and the positive technical factor, investors may want to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vor-biopharma-inc-vor-technical-145502570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2505738621","title":"Vor Biopharma Files Secondary Common Stock Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2505738621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505738621?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 06:11","pubTimestamp":1737497504,"startTime":"0","endTime":"0","summary":"Vor Biopharma  filed a registration statement Tuesday covering the potential resale of up to 125.7 million common shares of the company from time to time by certain stockholders.The statement consists of roughly 55.9 million shares held by the selling stockholders and 69.8 million shares issuable upon the exercise of certain outstanding warrants, the company said.The company will not receive any proceeds from the resale of stock, but will receive proceeds from the exercise of warrants, which will be used to fund clinical and preclinical development of candidate pipeline and for general corporate purposes.Vor Biopharma shares were down over 4% in after-hours activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2501277873","title":"BRIEF-Vor Bio Appoints Erez Kalir To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501277873","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501277873?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 22:32","pubTimestamp":1736346731,"startTime":"0","endTime":"0","summary":"BRIEF-Vor Bio Appoints Erez Kalir To Its Board Of DirectorsJan 8  - Vor Biopharma Inc VOR.O:VOR BIO APPOINTS LIFE SCIENCES AND TECHNOLOGY INVESTOR AND ENTREPRENEUR, MR. EREZ KALIR TO ITS BOARD OF DIRECTORSSource text: nGNX2L77MZFurther company coverage: VOR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA31T6C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vorbio.com","stockEarnings":[{"period":"1week","weight":0.0425},{"period":"1month","weight":-0.2136},{"period":"3month","weight":-0.5113},{"period":"6month","weight":-0.058},{"period":"1year","weight":-0.6243},{"period":"ytd","weight":-0.4144}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049009},{"month":2,"riseRate":0.5,"avgChangeRate":-0.021517},{"month":3,"riseRate":0.2,"avgChangeRate":-0.142709},{"month":4,"riseRate":0,"avgChangeRate":-0.18774},{"month":5,"riseRate":0.25,"avgChangeRate":-0.168862},{"month":6,"riseRate":0.25,"avgChangeRate":-0.134351},{"month":7,"riseRate":0,"avgChangeRate":-0.123744},{"month":8,"riseRate":0.5,"avgChangeRate":0.013788},{"month":9,"riseRate":0.25,"avgChangeRate":-0.127012},{"month":10,"riseRate":0.75,"avgChangeRate":0.068664},{"month":11,"riseRate":0.25,"avgChangeRate":-0.077067},{"month":12,"riseRate":1,"avgChangeRate":0.250694}],"exchange":"NASDAQ","name":"Vor Biopharma Inc.","nameEN":"Vor Biopharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vor Biopharma Inc.,VOR,Vor Biopharma Inc.股票,Vor Biopharma Inc.股票老虎,Vor Biopharma Inc.股票老虎国际,Vor Biopharma Inc.行情,Vor Biopharma Inc.股票行情,Vor Biopharma Inc.股价,Vor Biopharma Inc.股市,Vor Biopharma Inc.股票价格,Vor Biopharma Inc.股票交易,Vor Biopharma Inc.股票购买,Vor Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction